限制疫苗诱导性淋巴结病的筛查乳腺X线召回:单机构经验
单机构回顾性分析2304例接种COVID-19疫苗后行筛查乳腺X线患者,24例(1.0%)因同侧腋窝淋巴结病被召回,召回率低,无活检或恶性病例;淋巴结病出现随接种后天数增加而显著减少,ROC曲线提示28.5天为鉴别有无淋巴结病的最佳截断点。
要点
- 接种疫苗后筛查乳腺X线因腋窝淋巴结病召回率低(1.0%),且无恶性结局。
- 腋窝淋巴结病出现随接种后天数增加而显著减少(p < 0.001),ROC曲线提示28.5天为最佳截断点。
- 患者年龄、疫苗剂次或品牌与淋巴结病存在无显著差异。
核心结论
- 疫苗诱导性淋巴结病相关的召回率低,可限制不必要的检查、改善可及性并促进疫苗接种与筛查检查的灵活安排。
研究设计与样本
- 单机构回顾性研究,纳入2021年1月15日至5月31日期间接种至少1剂COVID-19疫苗后行筛查乳腺X线的患者共2304例;乳腺X线技师获取患者疫苗接种信息(剂次、品牌、接种手臂、日期)供阅片放射科医生参考;因腋窝淋巴结病召回的患者纳入分析,其他召回原因排除;追踪随访影像和结局。
关键影像表现/征象
- 24例(1.0%)因同侧腋窝淋巴结病被召回。
- 淋巴结病的存在与患者年龄、疫苗剂次或品牌无显著差异。
- 淋巴结病的存在随接种后天数增加而显著减少(p < 0.001)。
诊断标准与关键数值
- ROC曲线提示28.5天为区分乳腺X线上淋巴结病存在与否的最佳截断点。
- 24例召回中,13例(54.2%)结果为良性,2例(8.3%)仍在监测中,9例(37.5%)后续随访逾期。
- 无病例导致活检或恶性肿瘤。
临床应用与阅片要点
- 解读筛查乳腺X线时,结合患者COVID-19疫苗接种信息(剂次、品牌、接种手臂、日期)评估同侧腋窝淋巴结病。
- 淋巴结病出现随接种后天数增加而减少,ROC曲线提示28.5天为最佳截断点。
- 疫苗诱导性淋巴结病召回率低(1.0%),且无活检或恶性病例。
局限性
- 单机构回顾性研究。
- 24例召回中9例(37.5%)后续随访逾期,2例(8.3%)仍在监测中。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: Reported incidence of vaccine-induced adenopathy varies widely, with higher estimates in early reports and small series. Objective was to evaluate a large sample of vaccinated patients undergoing screening mammography, to determine callback rates associated with vaccine-induced adenopathy and their outcomes.
MATERIALS AND METHODS: Single-institution retrospective review of patients who received at least 1 dose of a COVID-19 vaccine prior to presentation for screening mammography from January 15 through May 31, 2021. Patient-related vaccination information (dose, brand, arm, date) was obtained by mammography technologists and available for interpreting radiologists. Patients recalled for axillary adenopathy were included; other causes for recall were excluded. Follow-up imaging and outcomes were tracked. Wilcoxon rank-sum test, Fisher exact test, multivariable logistic regression modeling, and receiver operating characteristic curve analyses were utilized. All tests were two-sided; p < 0.05 considered statistically significant.
RESULTS: Total of 2304 vaccinated patients underwent screening mammography; 24 (1.0%) recalled for ipsilateral adenopathy. There was no significant difference in presence of adenopathy associated with patient age, dose, or brand of vaccine. Presence of adenopathy significantly decreased as days from vaccination increased (p < 0.001). Receiver operating characteristic curve suggested 28.5 days as the best cutoff point to distinguish presence or absence of adenopathy on mammogram. Of 24 callbacks, 13 (54.2%) had benign results, 2 (8.3%) are still undergoing surveillance, and 9 (37.5%) are overdue for subsequent follow-ups. No cases resulted in biopsy or malignancy.
CONCLUSION: Low recall rates related to vaccine-induced adenopathy are achievable and can limit unnecessary workups, improve access, and promote flexible timing of vaccinations and screening exams.
引用
- Maimone, Robinson, Advani, et al. Limiting Screening Mammography Recalls for Vaccine-Induced Adenopathy, a Single Institution Experience. Acad Radiol. 2022. PMID: 35090829. doi:10.1016/j.acra.2021.12.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。